The startup is developing medicines designed to overstress cellular pathways to the point tumor cells die, an approach the biotech calls “activation lethality.” ...

The company said data for its Wegovy competitor was promising enough to move the drug into late-stage testing, triggering a stock jump that added billions to Amgen’s market value.

Conversations at this year's J.P. Morgan Healthcare Conference led to a $1 billion buyout that Mariana's CEO described as a "perfect marriage." ...

Newly disclosed Phase 3 results presented Friday match findings the biotech disclosed last year, while offering a more comprehensive look at how its drug stacks up to rival therapies.

Jeffrey Glazer expressed his enthusiasm about the collaboration, saying, "This exclusive licensing agreement with Georgetown University marks a pivotal moment for Aubex Therapeutics. ATX100 has ...

First quarter sales of the in-demand obesity drug were down slightly compared to the fourth quarter last year, as the company tries to meet demand.

Metagenomi said the companies’ decision to part ways followed a “strategic prioritization” undertaken by Moderna, which has made several investments in gene editing research in recent years.

The company, BridgeBio Oncology Therapeutics, has one drug in the clinic and hopes to soon advance two other candidates.

This flexible solution automates manual processes, supporting diverse manufacturing tasks. It's programmable for various processes, including optimized cell culture expansion and streamlining ...

The funding will help Reunion pay for a mid-stage study testing its most advanced medicine — essentially a synthetic version of the hallucinogenic psilocin — in women with postpartum depression.

Sales of the shingles vaccine Shingrix and the RSV shot Arexvy helped fuel quarterly revenue totals that surpassed analyst expectations, though the company warned momentum could slow in the months ...